A real-world single-center, retrospective study of safety and sustained virologic response in geriatric patients on DAA regimens
Latest Information Update: 24 May 2020
At a glance
- Drugs Daclatasvir (Primary) ; Dasabuvir/ombitasvir/paritaprevir/ritonavir (Primary) ; Elbasvir/grazoprevir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 24 May 2020 New trial record
- 13 May 2020 Results published in the Digestive Diseases and Sciences